|
|||||
|
|
Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure |
|
| Authors: | Andrew E. Ajani Thomas H. Marwick Henry Krum |
| Affiliation: | aDepartment of Cardiology, Royal Melbourne Hospital, Melbourne, Australia bNational Health Medical Research Council, Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia cUniversity of Queensland Department of Medicine, Princess Alexandra Hospital, Brisbane, Australia |
| Abstract: | Heart failure (HF) in association with acute myocardial infarction is an emerging clinical problem. The benefits of aldosterone blockade have now been extended, with the selective aldosterone antagonist eplerenone demonstrating reduced mortality compared to placebo, in patients with post-myocardial infarction HF. The evidence supporting this agent will be briefly reviewed, followed by a discussion on the clinical implications of aldosterone antagonists in this clinical setting. |
| Keywords: | Aldosterone antagonists Heart failure Myocardial infarction |
| 本文献已被 ScienceDirect 等数据库收录！ | |